Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:AVIR NASDAQ:ENTA NASDAQ:ENTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.45-4.6%$1.59$1.18▼$2.66$404.56M2.041.12 million shs716,999 shsAVIRAtea Pharmaceuticals$4.73-0.4%$4.55$2.78▼$6.45$380.13M0.31336,810 shs381,461 shsENTAEnanta Pharmaceuticals$12.78-1.3%$13.20$6.45▼$17.15$376.57M0.96223,332 shs104,647 shsENTXEntera Bio$2.05-3.8%$1.49$0.91▼$3.22$104.99M1.43255,851 shs163,301 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-4.61%+0.69%-9.66%+0.69%-45.90%AVIRAtea Pharmaceuticals-0.42%-2.87%+5.60%-13.53%+35.53%ENTAEnanta Pharmaceuticals-1.31%-6.99%-6.85%-3.98%+65.33%ENTXEntera Bio-3.76%+3.54%+33.12%+83.04%+6.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.45-4.6%$1.59$1.18▼$2.66$404.56M2.041.12 million shs716,999 shsAVIRAtea Pharmaceuticals$4.73-0.4%$4.55$2.78▼$6.45$380.13M0.31336,810 shs381,461 shsENTAEnanta Pharmaceuticals$12.78-1.3%$13.20$6.45▼$17.15$376.57M0.96223,332 shs104,647 shsENTXEntera Bio$2.05-3.8%$1.49$0.91▼$3.22$104.99M1.43255,851 shs163,301 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-4.61%+0.69%-9.66%+0.69%-45.90%AVIRAtea Pharmaceuticals-0.42%-2.87%+5.60%-13.53%+35.53%ENTAEnanta Pharmaceuticals-1.31%-6.99%-6.85%-3.98%+65.33%ENTXEntera Bio-3.76%+3.54%+33.12%+83.04%+6.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.89Moderate Buy$8.75503.45% UpsideAVIRAtea Pharmaceuticals 2.50Moderate BuyN/AN/AENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2958.73% UpsideENTXEntera Bio 2.00Hold$9.00339.02% UpsideCurrent Analyst Ratings BreakdownLatest ENTX, AUTL, ENTA, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026AVIRAtea Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026ENTAEnanta Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/17/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$92.62M4.17N/AN/A$0.67 per share2.16AVIRAtea PharmaceuticalsN/AN/AN/AN/A$3.53 per shareN/AENTAEnanta Pharmaceuticals$65.32M5.69N/AN/A$3.03 per share4.22ENTXEntera Bio$40K2,526.11N/AN/A$0.29 per share7.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-128.59%-46.25%8/11/2026 (Estimated)AVIRAtea Pharmaceuticals-$158.35M-$2.11N/AN/AN/AN/A-57.01%-51.49%8/6/2026 (Estimated)ENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)ENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%8/14/2026 (Estimated)Latest ENTX, AUTL, ENTA, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026ENTXEntera Bio-$0.08N/AN/AN/AN/AN/A8/11/2026Q2 2026AUTLAutolus Therapeutics-$0.22N/AN/AN/A$29.74 millionN/A8/10/2026Q3 2026ENTAEnanta Pharmaceuticals-$0.5095N/AN/AN/A$16.76 millionN/A8/6/2026Q2 2026AVIRAtea Pharmaceuticals-$0.56N/AN/AN/A$33.03 millionN/A5/15/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/12/2026Q1 2026AVIRAtea Pharmaceuticals-$0.60-$0.57+$0.03-$0.57$22.42 millionN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A5.805.28AVIRAtea PharmaceuticalsN/A7.897.89ENTAEnanta PharmaceuticalsN/A3.843.84ENTXEntera BioN/A7.937.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%AVIRAtea Pharmaceuticals86.67%ENTAEnanta Pharmaceuticals94.99%ENTXEntera Bio14.11%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%AVIRAtea Pharmaceuticals21.60%ENTAEnanta Pharmaceuticals11.48%ENTXEntera Bio10.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.16 million197.75 millionOptionableAVIRAtea Pharmaceuticals7080.03 million62.74 millionOptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableENTXEntera Bio2049.29 million44.08 millionOptionableENTX, AUTL, ENTA, and AVIR HeadlinesRecent News About These CompaniesEntera Bio Stock Rallies 35% in a Month: Here's What You Should KnowJuly 21, 2026 | zacks.comShort Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 107.8%July 15, 2026 | marketbeat.comAfter Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?July 15, 2026 | markets.businessinsider.comAmerica's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)July 8, 2026 | markets.businessinsider.comPositive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to MarketJune 23, 2026 | globenewswire.comENTX stock on track for best day in over 5 years — what’s driving the rally?June 22, 2026 | msn.comEntera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with ...June 22, 2026 | markets.businessinsider.comEntera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with OsteoporosisJune 22, 2026 | globenewswire.comAfter Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?June 20, 2026 | theglobeandmail.comEntera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026June 16, 2026 | globenewswire.comENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)June 15, 2026 | finance.yahoo.comEntera Bio Ltd. Reports Positive Phase 1 Results for EB613 as Potential First Oral Treatment for Osteoporosis at ENDO 2026June 15, 2026 | quiverquant.comQEntera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)June 2, 2026 | theglobeandmail.comEntera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting ...May 28, 2026 | markets.businessinsider.comEntera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for PresentationMay 28, 2026 | globenewswire.comEntera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide ProgramsMay 8, 2026 | globenewswire.comEntera Bio (ENTX) Upgraded to Buy: Here's What You Should KnowApril 29, 2026 | zacks.comEntera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet TranscriptApril 20, 2026 | seekingalpha.comBriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet OpportunityApril 20, 2026 | globenewswire.comEntera Bio Ltd. to Host Virtual Webinar on Osteoporosis Treatment and EB613, Its Lead Oral Anabolic CandidateApril 14, 2026 | quiverquant.comQEntera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613April 14, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 20262 AI Stocks That Could Benefit as AI Moves Beyond the Data CenterBy Thomas Hughes | July 5, 2026Apple Just Handed These 4 Memory Stocks Their Best News of the YearBy Bridget Bennett | June 28, 2026AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetBy Jeffrey Neal Johnson | July 10, 2026The AI Chip Sell-Off Looks Scary, But the Real Story May Be LiquidityBy Jeffrey Neal Johnson | July 7, 2026ENTX, AUTL, ENTA, and AVIR Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.45 -0.07 (-4.61%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.46 +0.01 (+0.34%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Atea Pharmaceuticals NASDAQ:AVIR$4.73 -0.02 (-0.42%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.68 -0.06 (-1.16%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$12.78 -0.17 (-1.31%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$12.75 -0.03 (-0.23%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Entera Bio NASDAQ:ENTX$2.05 -0.08 (-3.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.03 -0.02 (-1.12%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
